

Javed Butler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1284958/publications.pdf>

Version: 2024-02-01

590
papers

55,875
citations

4960

84
h-index

1568

217
g-index

591
all docs

591
docs citations

591
times ranked

33883
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
3	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821
4	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
5	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803.	2.8	2,256
6	Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2013, 6, 606-619.	3.9	2,206
7	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
8	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161.	1.6	2,130
9	The Global Health and Economic Burden of Hospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	2.8	1,640
10	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829.	13.7	816
11	Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 351-366.	2.8	775
12	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	27.0	753
13	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	7.1	630
14	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488.	2.8	549
15	Mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 2017, 14, 238-250.	13.7	525
16	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	13.7	425
17	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	2.8	424
18	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. JAMA - Journal of the American Medical Association, 2013, 310, 2533.	7.4	410

#	ARTICLE	IF	CITATIONS
19	Myocardial Interstitial Fibrosis in Heart Failure. Journal of the American College of Cardiology, 2018, 71, 1696-1706.	2.8	406
20	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1085.	7.4	403
21	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	1.7	362
22	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 73, 2365-2383.	2.8	327
23	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	7.4	288
24	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	2.2	285
25	Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534.	1.7	283
26	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology, 2017, 2, 1025.	6.1	280
27	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 136-145.	4.1	265
28	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 76, 280-288.	2.8	259
29	Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039.	1.6	252
30	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002661.	3.9	241
31	The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology, 2015, 12, 220-229.	13.7	238
32	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336.	1.6	222
33	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
34	Incident Heart Failure Prediction in the Elderly. Circulation: Heart Failure, 2008, 1, 125-133.	3.9	216
35	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	7.1	205
36	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	6.1	199

#	ARTICLE	IF	CITATIONS
37	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	2.2	199
38	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
39	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
40	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	2.8	193
41	Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 464-472.	4.1	179
42	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	174
43	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	7.4	170
44	Reframing the association and significance of comorbidities in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 744-758.	7.1	169
45	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
46	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995.	6.1	164
47	Epidemiology of Incident Heart Failure in a Contemporary Elderly Cohort. <i>Archives of Internal Medicine</i> , 2009, 169, 708.	3.8	161
48	Cardiovascular Aging and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 804-813.	2.8	160
49	Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 935-944.	2.8	160
50	Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, 868-875.	1.7	159
51	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	8.6	157
52	Evaluation of the effect of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Retarded trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
53	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. <i>JAMA Cardiology</i> , 2018, 3, 1011.	6.1	146
54	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. <i>Circulation Research</i> , 2017, 120, 332-340.	4.5	144

#	ARTICLE	IF	CITATIONS
55	Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , 2019, 21, 163-171.	7.1	144
56	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	2.2	144
57	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 704-712.	2.8	142
58	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	4.1	141
59	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.1	139
60	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed. <i>JAMA Cardiology</i> , 2021, 6, 743.	6.1	125
61	Therapeutic Targets in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2188-2198.	2.8	124
62	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 798-809.	4.5	124
63	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 165-175.	4.1	120
64	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	2.2	117
65	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	2.8	116
66	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines—Heart Failure registry. <i>American Heart Journal</i> , 2016, 182, 9-20.	2.7	115
67	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
68	Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008335.	3.9	113
69	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002843.	3.9	109
70	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , 2019, 7, 1-12.	4.1	109
71	Coenzyme Q10 and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002639.	3.9	108
72	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. <i>Nature Medicine</i> , 2022, 28, 809-813.	30.7	107

#	ARTICLE	IF	CITATIONS
73	Validation of clinical scores for right ventricular failure prediction after implantation of continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1595-1603.	0.6	106
74	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
75	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	2.8	105
76	Global left atrial failure in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1307-1320.	7.1	104
77	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3370-3372.	2.8	102
78	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H1033-H1042.	3.2	101
79	The Importance of NLRP3 Inflammasome in Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 586-593.	1.7	97
80	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. <i>International Journal of Cardiology</i> , 2014, 172, 115-121.	1.7	96
81	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	2.2	96
82	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	7.1	95
83	Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 237-248.	4.1	94
84	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	2.8	94
85	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.	2.8	94
86	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
87	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	2.8	90
88	Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 9-13.	7.3	90
89	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	4.1	88
90	Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic. <i>Journal of Cardiac Failure</i> , 2020, 26, 462-463.	1.7	87

#	ARTICLE	IF	CITATIONS
91	Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 1166-1187.	2.8	87
92	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	2.8	86
93	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. European Journal of Heart Failure, 2015, 17, 1231-1239.	7.1	85
94	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. European Journal of Heart Failure, 2017, 19, 782-791.	7.1	84
95	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. JACC: Heart Failure, 2017, 5, 1-13.	4.1	84
96	Advance Directives Among Hospitalized Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 112-121.	4.1	78
97	Empagliflozin and Major Renal Outcomes in Heart Failure. New England Journal of Medicine, 2021, 385, 1531-1533.	27.0	78
98	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	6.1	76
99	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure, 2020, 7, 3298-3309.	3.1	76
100	Concomitant Diabetes Mellitus and Heart Failure. Current Problems in Cardiology, 2015, 40, 7-43.	2.4	75
101	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. JACC: CardioOncology, 2019, 1, 54-65.	4.0	74
102	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. Journal of the American College of Cardiology, 2021, 78, 142-152.	2.8	74
103	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. European Journal of Heart Failure, 2016, 18, 54-65.	7.1	73
104	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. European Journal of Heart Failure, 2020, 22, 472-485.	7.1	71
105	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 999-1005.	7.1	71
106	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	2.2	71
107	Population Risk Prediction Models for Incident Heart Failure. Circulation: Heart Failure, 2015, 8, 438-447.	3.9	69
108	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3029-3039.	2.8	69

#	ARTICLE	IF	CITATIONS
109	Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor. JACC: Heart Failure, 2015, 3, 193-201.	4.1	68
110	Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1032-1042.	7.1	68
111	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	7.4	68
112	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	7.1	67
113	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65
114	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	7.1	65
115	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
116	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
117	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 522.	6.1	62
118	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	1.6	61
119	Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. JAMA - Journal of the American Medical Association, 2014, 312, 789.	7.4	58
120	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> (<scp>Vericiguat</scp> Global Study in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	7.1	58
121	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2014, 20, 319-326.	1.7	57
122	Medication dosing for heart failure with reduced ejection fraction â€” opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	7.1	57
123	Effect of Serelaxin on Mode of Death in Acute Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1591-1598.	2.8	56
124	Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 727-732.	2.8	56
125	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. Circulation, 2021, 143, 2370-2383.	1.6	56
126	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Failure Reviews, 2016, 21, 95-102.	3.9	55

#	ARTICLE	IF	CITATIONS
127	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. <i>Circulation: Heart Failure</i> , 2020, 13, e006605.	3.9	55
128	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1321-1332.	2.8	55
129	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. , 2017, 176, 32-39.		54
130	Comparison of Multidetector Computed Tomography and Two-Dimensional Transthoracic Echocardiography for Left Ventricular Assessment in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2007, 99, 247-249.	1.6	53
131	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1022-1031.	7.1	52
132	Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 528-537.	4.1	52
133	Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	52
134	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	2.8	52
135	Association of Physical Activity or Fitness With Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 853-861.	3.9	51
136	Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Meta-Analysis. <i>Journal of the American Heart Association</i> , 2015, 4, e001364.	3.7	51
137	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281.	1.7	50
138	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	2.8	50
139	Impact of Autonomic Regulation Therapy in Patients with Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005879.	3.9	50
140	Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. <i>JAMA Network Open</i> , 2020, 3, e2012469.	5.9	50
141	Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2076-2085.	2.8	50
142	Device Therapy in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 931-956.	2.8	50
143	Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. <i>Atherosclerosis</i> , 2016, 245, 181-186.	0.8	49
144	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088.	1.6	49

#	ARTICLE	IF	CITATIONS
145	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019, 139, 1458-1460.	1.6	49
146	Renal function estimation and Cockcroftâ€“Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€“OMicsâ€™™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181.	5.5	48
147	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 26-32.	1.7	48
148	Redefining Heart Failure With a Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1761.	7.4	48
149	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors forÂHeartÂFailure With Reduced EjectionÂFraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012.	2.8	48
150	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. <i>American Heart Journal</i> , 2022, 253, 86-98.	2.7	48
151	Management of Comorbid Diabetes Mellitus and Worsening Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2379.	7.4	47
152	Randomized Clinical Trial of an Integrated Self-Care Intervention for Persons With Heart Failure and Diabetes: Quality of Life and Physical Functioning Outcomes. <i>Journal of Cardiac Failure</i> , 2015, 21, 719-729.	1.7	47
153	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	47
154	Cardiovascular implications of COVID-19 versus influenza infection: a review. <i>BMC Medicine</i> , 2020, 18, 403.	5.5	47
155	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in HeartÂFailure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 127-136.	4.1	47
156	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid DiabetesÂMellitus and HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480.	4.1	47
157	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	46
158	Postmarketing Adverse Events Related to the CardioMEMS HF System. <i>JAMA Cardiology</i> , 2017, 2, 1277.	6.1	46
159	Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. <i>Heart Failure Reviews</i> , 2022, 27, 337-344.	3.9	46
160	Comparing the Benefit of Novel Therapies Across Clinical Trials. <i>Circulation</i> , 2020, 142, 717-719.	1.6	46
161	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437.	1.7	46
162	Extent and distribution of coronary artery disease: A comparative study of invasive versus noninvasive angiography with computed angiography. <i>American Heart Journal</i> , 2007, 153, 378-384.	2.7	45

#	ARTICLE	IF	CITATIONS
163	Echocardiography, Natriuretic Peptides, and Risk for Incident Heart Failure in Older Adults. JACC: Cardiovascular Imaging, 2012, 5, 131-140.	5.3	45
164	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. European Journal of Heart Failure, 2016, 18, 1072-1081.	7.1	44
165	Risk Profiles in Heart Failure. Circulation: Heart Failure, 2020, 13, e007132.	3.9	44
166	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. American Heart Journal, 2017, 189, 177-183.	2.7	43
167	Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event. Advances in Therapy, 2020, 37, 4015-4032.	2.9	43
168	Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. JACC: Heart Failure, 2021, 9, 28-38.	4.1	43
169	Extracellular Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate Minimally. JACC: Cardiovascular Imaging, 2020, 13, 2343-2354.	5.3	42
170	Atrial Fibrillation and Declining Physical Performance in Older Adults. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003525.	4.8	41
171	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart OMICS in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	3.7	41
172	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. ESC Heart Failure, 2020, 7, 76-84.	3.1	41
173	Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrology Dialysis Transplantation, 2021, 36, 137-150.	0.7	41
174	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	7.1	41
175	Strategies and Opportunities for Drug Development in Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1593.	7.4	40
176	Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2016, 5, .	3.7	40
177	Therapeutic Manipulation of Myocardial Metabolism. Journal of the American College of Cardiology, 2021, 77, 2022-2039.	2.8	40
178	The Cardio-Renal Interrelationship. Progress in Cardiovascular Diseases, 2017, 59, 636-648.	3.1	39
179	Relation of Living in a Food Desert to Recurrent Hospitalizations in Patients With Heart Failure. American Journal of Cardiology, 2019, 123, 291-296.	1.6	39
180	Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. Journal of Cardiovascular Pharmacology, 2020, 76, 313-320.	1.9	39

#	ARTICLE	IF	CITATIONS
181	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.	2.2	39
182	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	2.0	38
183	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005875.	3.9	38
184	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	2.8	38
185	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	2.2	38
186	Need for Increased Awareness and Evidence-Based Therapies for Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2035.	7.4	37
187	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. <i>Circulation: Heart Failure</i> , 2018, 11, e004312.	3.9	37
188	“Time is prognosis”™ in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	3.1	37
189	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , 2018, 11, e005400.	3.9	36
190	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002797.	8.4	36
191	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.	2.8	36
192	Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1354-1362.	1.8	35
193	Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. <i>Clinical Research in Cardiology</i> , 2016, 105, 489-507.	3.3	35
194	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928.	8.6	35
195	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	7.1	35
196	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	3.9	34
197	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	2.7	34
198	Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831.	3.9	34

#	ARTICLE	IF	CITATIONS
199	Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002115.	3.9	34
200	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1861-1871.	2.8	34
201	Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 1757-1766.	0.4	34
202	Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. <i>Internal and Emergency Medicine</i> , 2015, 10, 965-972.	2.0	33
203	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291.	7.1	33
204	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	3.9	33
205	Use of sodium-glucose cotransporter 2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 604-617.	7.1	33
206	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022.	7.1	33
207	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.	2.2	33
208	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265.	1.7	32
209	Cardiomyopathy and Heart Failure in Patients With HIV Infection. <i>Canadian Journal of Cardiology</i> , 2019, 35, 299-309.	1.7	32
210	Patiomer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	7.1	32
211	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.	7.1	32
212	Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation. <i>Annals of Internal Medicine</i> , 2022, 175, 1073-1082.	3.9	32
213	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 428-438.	1.7	31
214	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 933-941.	4.1	31
215	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020, 22, 1065-1075.	7.1	31
216	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	4.1	30

#	ARTICLE	IF	CITATIONS
217	Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	4.1	30
218	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circulation: Heart Failure, 2021, 14, e008100.	3.9	30
219	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	7.1	30
220	Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal, 2022, 43, 2984-2993.	2.2	30
221	Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444.	3.9	29
222	β_1 -Adrenoreceptor Autoantibodies in Heart Failure. Circulation: Heart Failure, 2020, 13, e006155.	3.9	29
223	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. European Journal of Heart Failure, 2021, 23, 1468-1476.	7.1	29
224	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology, 2022, 10, 35-45.	11.4	29
225	Nitrate Therapy for Heart Failure. JACC: Heart Failure, 2013, 1, 183-191.	4.1	28
226	Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. ESC Heart Failure, 2018, 5, 549-551.	3.1	28
227	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e006946.	3.9	28
228	Endpoints in Heart Failure Drug Development. JACC: Heart Failure, 2020, 8, 429-440.	4.1	28
229	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182.	1.6	28
230	Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women. American Journal of Cardiology, 2015, 116, 474-480.	1.6	27
231	High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. European Journal of Heart Failure, 2017, 19, 748-755.	7.1	27
232	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610.	7.1	27
233	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. European Journal of Heart Failure, 2019, 21, 1426-1433.	7.1	27
234	Salt, No Salt, or Less Salt for Patients With Heart Failure?. American Journal of Medicine, 2020, 133, 32-38.	1.5	27

#	ARTICLE	IF	CITATIONS
235	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	7.1	27
236	Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410.	3.9	27
237	Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , 2015, 170, 263-272.e2.	2.7	26
238	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016, 21, 455-462.	3.9	26
239	Prognostic significance of ¹²³ I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 384-390.	1.2	26
240	Echocardiography in Acute Heart Failure: Current Perspectives. <i>Journal of Cardiac Failure</i> , 2016, 22, 82-94.	1.7	26
241	A Scientific Analysis of the 100 Citation Classics of Valvular Heart Disease. <i>American Journal of Cardiology</i> , 2017, 120, 1440-1449.	1.6	26
242	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1060-1073.	1.6	26
243	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	26
244	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	4.1	26
245	In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. <i>European Journal of Heart Failure</i> , 2022, 24, 227-229.	7.1	26
246	Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248.	7.1	26
247	Improved Outcomes for Women on the Heart Transplant Wait List in the Modern Era. <i>Journal of Cardiac Failure</i> , 2015, 21, 555-560.	1.7	25
248	The Vulnerable Phase of Heart Failure. <i>American Journal of Therapeutics</i> , 2018, 25, e456-e464.	0.9	25
249	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 371-380.	1.7	25
250	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006833.	3.9	25
251	The Right Ventricular Function After Left Ventricular Assist Device (RVF-LVAD) study: rationale and preliminary results. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 429-437.	1.2	24
252	Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , 2018, 11, e005629.	3.9	24

#	ARTICLE	IF	CITATIONS
253	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24
254	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1675-1683.	7.1	24
255	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	3.9	24
256	Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. <i>Advances in Therapy</i> , 2015, 32, 971-982.	2.9	23
257	Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 350-352.	7.1	23
258	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150.	1.6	23
259	Influence of atrial fibrillation on postdischarge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	7.1	23
260	Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , 2018, 269, 265-271.	1.7	23
261	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 159-161.	1.6	23
262	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	4.1	23
263	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	3.8	23
264	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1587-1598.	2.8	23
265	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180.	7.1	23
266	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	2.3	23
267	Relation of the Metabolic Syndrome to Quantity of Coronary Atherosclerotic Plaque. <i>American Journal of Cardiology</i> , 2008, 101, 1127-1130.	1.6	22
268	Trends in Heart Failure Clinical Trials From 2001 to 2012. <i>Journal of Cardiac Failure</i> , 2016, 22, 171-179.	1.7	22
269	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
270	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 78-86.	1.7	22

#	ARTICLE	IF	CITATIONS
271	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. American Heart Journal, 2020, 220, 41-50.	2.7	22
272	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. JAMA Cardiology, 2021, 6, 267.	6.1	22
273	Contextualizing Risk Among Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2021, 326, 2261.	7.4	22
274	The need for increased pragmatism in cardiovascular clinical trials. Nature Reviews Cardiology, 2022, 19, 737-750.	13.7	22
275	The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure: Implications for Management of Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, 399-407.	1.9	21
276	Comparing Sodium Intake Strategies in Heart Failure. Circulation: Heart Failure, 2015, 8, 636-645.	3.9	21
277	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	3.1	21
278	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. JACC: Heart Failure, 2018, 6, 813-822.	4.1	21
279	Timely Management of New-Onset Heart Failure. Circulation, 2019, 140, 621-623.	1.6	21
280	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	1.6	21
281	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <sc>EMPEROR&Preserved</sc> trial. European Journal of Heart Failure, 2021, 23, 1798-1799.	7.1	21
282	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology, 2022, 79, 432-444.	2.8	21
283	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	2.8	21
284	Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. JACC: Heart Failure, 2022, 10, 350-362.	4.1	21
285	Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the <sc>EMPEROR&Preserved</sc> trial. European Journal of Heart Failure, 2022, 24, 1869-1878.	7.1	21
286	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	2.8	21
287	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. American Heart Journal, 2015, 169, 305-314.	2.7	20
288	Antecedents of self-care in adults with congenital heart defects. International Journal of Cardiology, 2015, 201, 610-615.	1.7	20

#	ARTICLE	IF	CITATIONS
289	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. International Journal of Cardiology, 2016, 216, 46-51.	1.7	20
290	SPECT and PET in ischemic heart failure. Heart Failure Reviews, 2017, 22, 243-261.	3.9	20
291	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	20
292	Why Clinicians Should Care About the Cardiac Interstitium. JACC: Cardiovascular Imaging, 2019, 12, 2305-2318.	5.3	20
293	Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 58	1.6	20
294	Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal, 2020, 41, 3398-3401.	2.2	20
295	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes, Obesity and Metabolism, 2020, 22, 1141-1150.	4.4	20
296	Advanced cancer is also a heart failure syndrome: a hypothesis. European Journal of Heart Failure, 2021, 23, 140-144.	7.1	20
297	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 42-51.	4.1	20
298	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. JACC: Heart Failure, 2022, 10, 266-275.	4.1	20
299	An Economic Evaluation of a Self-Care Intervention in Persons With Heart Failure and Diabetes. Journal of Cardiac Failure, 2015, 21, 730-737.	1.7	19
300	Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. Journal of Cardiac Failure, 2016, 22, 340-346.	1.7	19
301	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). American Journal of Cardiology, 2019, 124, 1900-1906.	1.6	19
302	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. Canadian Journal of Cardiology, 2019, 35, 1097-1105.	1.7	19
303	Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. International Journal of Cardiology, 2020, 300, 245-251.	1.7	19
304	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. Journal of the American Heart Association, 2020, 9, e014990.	3.7	19
305	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398.	7.1	19
306	Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. Journal of the American Heart Association, 2021, 10, e017320.	3.7	19

#	ARTICLE	IF	CITATIONS
307	Systemic inflammation and functional capacity in elderly heart failure patients. <i>Clinical Research in Cardiology</i> , 2018, 107, 362-367.	3.3	18
308	Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 152-154.	1.6	18
309	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>JAMA Cardiology</i> , 2021, 6, 200.	6.1	18
310	Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. <i>European Journal of Heart Failure</i> , 2021, 23, 145-153.	7.1	18
311	Thromboembolism in Heart Failure Patients in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2021, 9, 243-253.	4.1	18
312	Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	17
313	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , 2018, 20, 1068-1071.	7.1	17
314	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947.	1.6	17
315	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2018, 25, e475-e486.	0.9	17
316	Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1247-1251.	7.1	17
317	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020, 180, 141.	5.1	17
318	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2432-2447.	2.8	17
319	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , 2021, 23, 1250-1255.	7.1	17
320	Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post Hoc Analysis of the ATHENA Trial. <i>European Journal of Heart Failure</i> , 2022, , .	7.1	17
321	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , 2015, 17, 760-763.	7.1	16
322	The Potential Role of Natriuretic Peptide-Guided Management for Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 233-239.	1.7	16
323	Platelet-Derived Growth Factor in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 355-369.	1.8	16
324	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective. <i>ESC Heart Failure</i> , 2020, 7, 3261-3267.	3.1	16

#	ARTICLE	IF	CITATIONS
325	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. Heart Lung and Circulation, 2021, 30, 786-794.	0.4	16
326	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. Journal of Cardiac Failure, 2021, 27, 2-19.	1.7	16
327	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676.	1.7	16
328	Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. European Journal of Heart Failure, 2022, 24, 455-462.	7.1	16
329	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Journal of Cardiac Failure, 2022, 28, 370-384.	1.7	16
330	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 782-790.	7.1	16
331	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. JACC: Heart Failure, 2022, 10, 198-210.	4.1	16
332	Inotrope Use and Outcomes Among Patients Hospitalized for Heart Failure: Impact of Systolic Blood Pressure, Cardiac Index, and Etiology. Journal of Cardiac Failure, 2014, 20, 593-601.	1.7	15
333	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. Circulation: Heart Failure, 2016, 9, .	3.9	15
334	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	15
335	Exercise Capacity, Heart Failure Risk, and Mortality in Older Adults: The Health ABC Study. American Journal of Preventive Medicine, 2017, 52, 144-153.	3.0	15
336	Health Status Variation Across Practices in Outpatients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004668.	2.2	15
337	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. Journal of Cardiovascular Medicine, 2019, 20, 223-225.	1.5	15
338	Predictors of heart failure development in type 2 diabetes. Current Opinion in Cardiology, 2019, 34, 578-583.	1.8	15
339	Therapeutic Advances in the Management of Cardiogenic Shock. American Journal of Therapeutics, 2019, 26, e234-e247.	0.9	15
340	Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. European Journal of Heart Failure, 2020, 22, 1600-1610.	7.1	15
341	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. Circulation: Heart Failure, 2020, 13, e006827.	3.9	15
342	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. JAMA Cardiology, 2021, 6, 354.	6.1	15

#	ARTICLE	IF	CITATIONS
343	Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 146, 36-47.	1.6	15
344	Treatment patterns and clinical outcomes among patients <math>\geq 65\% years with a worsening heart failure event. <i>European Journal of Heart Failure</i> , 2021, 23, 1334-1342.	7.1	15
345	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	7.1	15
346	Association of electrocardiogram abnormalities and incident heart failure events. <i>American Heart Journal</i> , 2014, 167, 869-875.e3.	2.7	14
347	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
348	Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 1207-1213.	1.6	14
349	Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. <i>Current Heart Failure Reports</i> , 2018, 15, 191-197.	3.3	14
350	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , 2018, 36, 1463-1473.	3.3	14
351	Clinical aspects of heart failure in individuals with diabetes. <i>Diabetologia</i> , 2019, 62, 1529-1538.	6.3	14
352	Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. <i>European Journal of Heart Failure</i> , 2019, 21, 121-124.	7.1	14
353	Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2486-2497.	2.6	14
354	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895.	1.7	14
355	Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. <i>American Journal of Medicine</i> , 2021, 134, 1068-1070.	1.5	14
356	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials. <i>JAMA Cardiology</i> , 2022, 7, 549.	6.1	14
357	Outcomes with empagliflozin in heart failure with preserved ejection fraction using ΔGFR-like endpoint definitions. <i>European Journal of Heart Failure</i> , 2022, 24, 1400-1405.	7.1	14
358	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>European Heart Journal</i> , 2022, 43, 2931-2945.	2.2	14
359	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016, 18, 185-191.	7.1	13
360	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. <i>Current Heart Failure Reports</i> , 2017, 14, 217-222.	3.3	13

#	ARTICLE	IF	CITATIONS
361	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	2.2	13
362	Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. <i>European Heart Journal Supplements</i> , 2019, 21, A20-A27.	0.1	13
363	Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?. <i>JACC: Heart Failure</i> , 2019, 7, 267-271.	4.1	13
364	Acutely decompensated versus acute heart failure: two different entities. <i>Heart Failure Reviews</i> , 2020, 25, 907-916.	3.9	13
365	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	3.1	13
366	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020, 43, 2684-2690.	8.6	13
367	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1243-1262.	4.4	13
368	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 741-753.	3.9	13
369	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 1583-1594.	6.3	13
370	Advanced cancer is also a heart failure syndrome: a hypothesis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 533-537.	7.3	13
371	Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1374-1381.	1.7	13
372	Iron Deficiency in CKD Without Concomitant Anemia. <i>Kidney International Reports</i> , 2021, 6, 2752-2762.	0.8	13
373	Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 485-493.	4.1	13
374	Serum chloride in heart failure: a salty prognosis. <i>European Journal of Heart Failure</i> , 2016, 18, 669-671.	7.1	12
375	The Three-Decade Long Journey in Heart Failure Drug Development. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 1-14.	1.8	12
376	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 340-346.	1.6	12
377	Novel Endpoints for Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 210-216.	3.3	12
378	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2018, 15, 44-52.	3.3	12

#	ARTICLE	IF	CITATIONS
379	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , 2018, 36, 63-72.	2.2	12
380	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	4.1	12
381	Victims of Success in Failure. <i>Circulation</i> , 2020, 142, 1129-1131.	1.6	12
382	Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006389.	3.9	12
383	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1451-1461.	7.1	12
384	Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. <i>ESC Heart Failure</i> , 2021, 8, 1915-1923.	3.1	12
385	Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. <i>Circulation</i> , 2021, 143, 2329-2331.	1.6	12
386	Maternal Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e021019.	3.7	12
387	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <sc>EMPA-REG OUTCOME</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784.	4.4	12
388	How well do we represent ourselves: an analysis of cardiology fellowships website content. <i>Future Cardiology</i> , 2020, 16, 281-287.	1.2	12
389	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016, 117, 1845-1850.	1.6	11
390	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776.	1.7	11
391	Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. <i>JAMA Cardiology</i> , 2017, 2, 1263.	6.1	11
392	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 783-792.	1.7	11
393	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	1.7	11
394	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , 2021, 8, 16-25.	3.1	11
395	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	1.8	11
396	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890.	2.2	11

#	ARTICLE	IF	CITATIONS
397	Impact of polyvascular disease with and without coexistent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of <sc>EMPAâ€REG OUTCOME</sc>. Diabetes, Obesity and Metabolism, 2021, 23, 1173-1181.	4.4	11
398	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESSâ€HF. Journal of the American Heart Association, 2020, 9, e015752.	3.7	11
399	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC: Heart Failure, 2022, 10, 1-11.	4.1	11
400	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153.	7.1	11
401	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Academic Emergency Medicine, 2016, 23, 922-931.	1.8	10
402	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. American Journal of Therapeutics, 2019, 26, e222-e233.	0.9	10
403	Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure. European Journal of Heart Failure, 2019, 21, 235-237.	7.1	10
404	History of Atrial Fibrillation and Trajectory of Decongestion in Acuteâ€Heart Failure. JACC: Heart Failure, 2019, 7, 47-55.	4.1	10
405	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 270-275.	1.7	10
406	Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. ESC Heart Failure, 2020, 7, 3531-3535.	3.1	10
407	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. Journal of the American College of Cardiology, 2020, 76, 2517-2521.	2.8	10
408	The Limitations of Symptom-based Heart Failure Management. Cardiac Failure Review, 2019, 5, 74-77.	3.0	10
409	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation: Heart Failure, 2021, 14, e008351.	3.9	10
410	Aspirin use is associated with increased risk for incident heart failure: a patientâ€level pooled analysis. ESC Heart Failure, 2022, 9, 685-694.	3.1	10
411	Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts. Circulation, 2022, 145, 268-278.	1.6	10
412	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation: Heart Failure, 2022, 15, .	3.9	10
413	Side effects and treatment initiation barriers of sodiumâ€glucose cotransporter 2 inhibitors in heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1625-1632.	7.1	10
414	Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. Expert Review of Cardiovascular Therapy, 2015, 13, 1075-1078.	1.5	9

#	ARTICLE	IF	CITATIONS
415	Pregnant women with heart disease: Placental characteristics and their association with fetal adverse events. <i>Acute Cardiac Care</i> , 2016, 18, 56-64.	0.2	9
416	Utility of positron emission tomography for drug development for heart failure. <i>American Heart Journal</i> , 2016, 175, 142-152.	2.7	9
417	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	1.7	9
418	Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 314-315.	11.4	9
419	The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure. <i>Circulation</i> , 2017, 136, 1459-1461.	1.6	9
420	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	1.7	9
421	Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , 2018, 20, 1379-1381.	7.1	9
422	Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 705-713.	0.9	9
423	Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. <i>Children</i> , 2021, 8, 322.	1.5	9
424	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021, 42, 2373-2383.	2.2	9
425	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <sc>HEAAL</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1477-1484.	7.1	9
426	Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of "too little, too late". <i>European Journal of Heart Failure</i> , 2021, 23, 1514-1517.	7.1	9
427	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 857538.	2.8	9
428	Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. <i>International Journal of Cardiology</i> , 2016, 218, 136-143.	1.7	8
429	Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	8
430	Heart failure guidelines: What's new?. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 316-323.	4.9	8
431	Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 537-560.	1.8	8
432	Integrating electronic health records into the study of heart failure: promises and pitfalls. <i>European Journal of Heart Failure</i> , 2017, 19, 1128-1130.	7.1	8

#	ARTICLE	IF	CITATIONS
433	A new educational program in heart failure drug development. Journal of Cardiovascular Medicine, 2018, 19, 411-421.	1.5	8
434	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 714-717.	4.1	8
435	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. Digital Biomarkers, 2020, 4, 45-59.	4.4	8
436	The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure. Circulation: Heart Failure, 2020, 13, e008030.	3.9	8
437	Clinical Associations of Vascular Stiffness, Microvascular Dysfunction, and Prevalent Cardiovascular Disease in a Black Cohort: The Jackson Heart Study. Journal of the American Heart Association, 2020, 9, e017018.	3.7	8
438	Temporal trends in risk profiles among patients hospitalized for heart failure. American Heart Journal, 2021, 232, 154-163.	2.7	8
439	Functional outcomes with Carillon device over 1Âyear in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCEâ€FMR trial. ESC Heart Failure, 2021, 8, 872-878.	3.1	8
440	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2021, 145, 165-168.	1.6	8
441	Physical Activity, Inflammation, Coronary Artery Calcification, and Incident Coronary Heart Disease in African Americans: Insights From the Jackson Heart Study. Mayo Clinic Proceedings, 2021, 96, 901-911.	3.0	8
442	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. Heart Failure Reviews, 2022, 27, 1147-1163.	3.9	8
443	The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from <scp>CHAMPâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 762-770.	7.1	8
444	Responder analysis for improvement in sixâ€minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 2022, , .	7.1	8
445	Defining changes in physical limitation from the patient perspective: insights from the <scp>VITALITYâ€HFpEF</scp> randomized trial. European Journal of Heart Failure, 2022, , .	7.1	8
446	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	2.2	8
447	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clinical Cardiology, 2022, 45, .	1.8	8
448	Heart Failure: A Global Pandemic and Not Just a Disease of the West. Heart Failure Clinics, 2015, 11, xiii-xiv.	2.1	7
449	Diagnosis and Prevention of Hypertensive Heart Failure. Heart Failure Clinics, 2019, 15, 435-445.	2.1	7
450	Novel potassium binders as enabling therapy in heart failure. European Journal of Heart Failure, 2019, 21, 550-552.	7.1	7

#	ARTICLE	IF	CITATIONS
451	Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. International Journal of Cardiology, 2020, 304, 116-121.	1.7	7
452	Recognizing the Significance of Outpatient Worsening Heart Failure. Journal of the American Heart Association, 2020, 9, e017485.	3.7	7
453	Benefitâ€“Risk Tradeoffs in Assessment of New Drugs and Devices. Circulation, 2020, 142, 1974-1988.	1.6	7
454	Challenges and Potential Improvements to Patient Access to Pharmaceuticals. Circulation, 2020, 142, 790-798.	1.6	7
455	The real world of <i>de novo</i> heart failure: the next frontier for heart failure clinical trials?. European Journal of Heart Failure, 2020, 22, 1786-1789.	7.1	7
456	SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Current Cardiology Reports, 2021, 23, 59.	2.9	7
457	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. American Heart Journal, 2021, 235, 82-96.	2.7	7
458	Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricularâ€“Enlargement. JACC: Heart Failure, 2021, 9, 453-462.	4.1	7
459	Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. European Journal of Heart Failure, 2021, 23, 1525-1528.	7.1	7
460	Health Systemâ€“Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. Journal of Cardiac Failure, 2022, , .	1.7	7
461	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. Current Heart Failure Reports, 2018, 15, 10-16.	3.3	6
462	Expanded algorithm for managing patients with acute decompensated heart failure. Heart Failure Reviews, 2018, 23, 597-607.	3.9	6
463	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	6
464	Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction. International Journal of Cardiology, 2018, 272, 250-254.	1.7	6
465	Design of a â€œLeanâ€“Case Report Form for Heartâ€“Failure Therapeutic Development. JACC: Heart Failure, 2019, 7, 913-921.	4.1	6
466	New treatments for hyperkalaemia: clinical use in cardiology. European Heart Journal Supplements, 2019, 21, A41-A47.	0.1	6
467	SGLT-2 inhibitors in heart failure: a new therapeutic avenue. Nature Medicine, 2019, 25, 1653-1654.	30.7	6
468	Cardiac Imaging in Dialysis Patients. Kidney Medicine, 2020, 2, 629-638.	2.0	6

#	ARTICLE	IF	CITATIONS
469	Ten lessons from the <scp>EMPEROR–Reduced</scp> trial. European Journal of Heart Failure, 2020, 22, 1991-1993.	7.1	6
470	Assessment of Heterogeneity in Heart Failure–Related Meta-Analyses. Circulation: Heart Failure, 2020, 13, e007070.	3.9	6
471	Istaroxime in acute heart failure: the holy grail is at HORIZON?. European Journal of Heart Failure, 2020, 22, 1694-1697.	7.1	6
472	Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. American Journal of Medicine, 2020, 133, 525-527.	1.5	6
473	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. ESC Heart Failure, 2021, 8, 26-36.	3.1	6
474	Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European Heart Journal, 2022, 43, 2968-2970.	2.2	6
475	Challenges and the innovations in the care of advanced heart failure patients during COVID-19. Heart Failure Reviews, 2022, 27, 235-238.	3.9	6
476	Effect of Carillon Mitral Contour System on patient–reported outcomes in functional mitral regurgitation: an individual participant data meta–analysis. ESC Heart Failure, 2021, 8, 1885-1891.	3.1	6
477	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 191-201.	1.7	6
478	Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. American Heart Journal, 2020, 230, 71-81.	2.7	6
479	Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy. Circulation: Heart Failure, 2022, 15, .	3.9	6
480	Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure. Heart Failure Clinics, 2014, 10, 565-576.	2.1	5
481	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. American Journal of Cardiology, 2015, 116, 1304-1310.	1.6	5
482	Updates on Device-Based Therapies for Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 53-60.	3.3	5
483	The Current Landscape of Atrial–Fibrillation and Atrial Flutter Clinical–Trials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	3.2	5
484	Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. PLoS ONE, 2019, 14, e0222868.	2.5	5
485	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). American Journal of Cardiology, 2019, 123, 1660-1666.	1.6	5
486	From <scp>PARADIGM</scp> to <scp>PARAGON</scp> further evidence supporting continuous heart failure spectrum. European Journal of Heart Failure, 2020, 22, 1536-1539.	7.1	5

#	ARTICLE	IF	CITATIONS
487	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. ESC Heart Failure, 2021, 8, 662-669.	3.1	5
488	Can we trust a smartwatch <scp>ECG</scp>? Potential and limitations. European Journal of Heart Failure, 2021, 23, 850-853.	7.1	5
489	Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007956.	2.2	5
490	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 916-923.	1.7	5
491	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	7.1	5
492	Response to Sexton: Inhibiting the Renin-“Angiotensin”-Aldosterone System in Patients With Heart Failure and Renal Dysfunction. Circulation: Heart Failure, 2014, 7, 537-540.	3.9	4
493	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2016, 22, 618-627.	1.7	4
494	Is Time of the Essence? The Impact of “Time of Hospital Presentation in Acute” Heart Failure. JACC: Heart Failure, 2018, 6, 298-307.	4.1	4
495	Past, present, and future of acute heart failure clinical trials “a high-risk population in search of a strategy. European Journal of Heart Failure, 2018, 20, 839-841.	7.1	4
496	Optimal Endpoints of Acute Heart Failure Therapy. American Journal of Therapeutics, 2018, 25, e465-e474.	0.9	4
497	Epirubicin and long-term heart failure risk in breast cancer survivors. European Journal of Heart Failure, 2018, 20, 1454-1456.	7.1	4
498	Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Pregnancy Hypertension, 2020, 21, 184-190.	1.4	4
499	Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. European Journal of Heart Failure, 2020, 22, 1019-1021.	7.1	4
500	Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications. Heart Failure Reviews, 2021, 26, 381-389.	3.9	4
501	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563.	1.7	4
502	Robustness of outcomes in trials evaluating sodium “glucose co-transporter 2 inhibitors for heart failure. ESC Heart Failure, 2022, , .	3.1	4
503	Updated Heart Failure Guidelines: Time for a Refresh. Circulation, 2022, 145, 1371-1373.	1.6	4
504	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. Current Heart Failure Reports, 2017, 14, 203-209.	3.3	3

#	ARTICLE	IF	CITATIONS
505	FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i72-i72.	0.7	3
506	Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1267-1269.	7.1	3
507	Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. <i>Current Diabetes Reports</i> , 2019, 19, 39.	4.2	3
508	Prescription drug spending and hospital use among Medicare beneficiaries with heart failure. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1452-1458.	3.0	3
509	Postâ€discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2020, 22, 164-167.	7.1	3
510	Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). <i>American Journal of Cardiology</i> , 2020, 136, 100-106.	1.6	3
511	The role of sodium glucose co-transporter inhibitors in heart failure prevention. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107811.	2.3	3
512	INTERVENEâ€CHF: feasibility study of individualized, risk stratificationâ€based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 849-860.	3.1	3
513	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIANâ€CHF Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017932.	3.7	3
514	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	2.7	3
515	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPTâ€CHF risk model. <i>ESC Heart Failure</i> , 2022, 9, 178-185.	3.1	3
516	Ejection fraction in heart failure: just become Emperor's new clothes?. <i>European Journal of Heart Failure</i> , 2022, 24, 351-352.	7.1	3
517	Hot Topics in Primary Care: Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. <i>Journal of Family Practice</i> , 2017, 66, S16-S21.	0.2	3
518	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€CHF. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	3
519	Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. <i>American Journal of Medicine</i> , 2014, 127, 574-578.	1.5	2
520	Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?. <i>European Journal of Heart Failure</i> , 2015, 17, 647-651.	7.1	2
521	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015, 116, 307-312.	1.6	2
522	Cardiac Contractility Modulation: The Next Cardiac Resynchronization Therapy or Another Renal Sympathetic Denervation?. <i>Journal of Cardiac Failure</i> , 2015, 21, 24-26.	1.7	2

#	ARTICLE	IF	CITATIONS
523	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. International Journal of Cardiology, 2016, 214, 16-18.	1.7	2
524	Diabetes Mellitus in Patients With Heart Failure. JACC: Heart Failure, 2017, 5, 25-27.	4.1	2
525	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 1760-1763.	7.1	2
526	Revisiting hyperkalaemia guidelines: rebuttal. European Journal of Heart Failure, 2018, 20, 1255-1255.	7.1	2
527	De novo heart failure: where the journey begins. European Journal of Heart Failure, 2019, 21, 1245-1247.	7.1	2
528	Reply. Journal of the American College of Cardiology, 2019, 74, 1426-1427.	2.8	2
529	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. European Journal of Heart Failure, 2019, 21, 1472-1476.	7.1	2
530	Targeting Mitochondrial Function in Heart Failure. JACC Basic To Translational Science, 2019, 4, 158-160.	4.1	2
531	Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). American Journal of Cardiology, 2020, 125, 82-86.	1.6	2
532	Angiotensin-neprilysin inhibition in de novo heart failure “starting off strong. European Journal of Heart Failure, 2020, 22, 313-314.	7.1	2
533	Heart Failure Prevention for All. Journal of the American College of Cardiology, 2020, 76, 1466-1467.	2.8	2
534	Sodium-glucose co-transporter 2 inhibitors: “a tale of two sisters”, diabetes and heart failure. European Journal of Heart Failure, 2020, 22, 1259-1262.	7.1	2
535	Orphan Drug Development in Cardiovascular Medicine. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006509.	2.2	2
536	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.6	2
537	Major Depression and Anxiety Among Patients Hospitalized With Heart Failure. American Journal of Cardiology, 2021, 142, 153-155.	1.6	2
538	Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure. International Journal of Cardiovascular Imaging, 2021, , 1.	1.5	2
539	Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction “time to think outside the heart. European Journal of Heart Failure, 2021, 23, 1552-1554.	7.1	2
540	Hypertensive Diseases in Pregnancy and Kidney Function Later in Life. Mayo Clinic Proceedings, 2022, 97, 78-87.	3.0	2

#	ARTICLE	IF	CITATIONS
541	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008072.	2.2	2
542	The Syndrome of Heart Failure With Preserved Systolic Function. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 232-233.	0.6	1
543	Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2018, 20, 97.	2.9	1
544	Questioning the Associations of Î³-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 781.	6.1	1
545	Midâ€‘regional proâ€‘atrial natriuretic peptide for diagnosis of heart failure in nonâ€‘acute settings: biomarkers plus clinical sense make good sense. <i>European Journal of Heart Failure</i> , 2019, 21, 1228-1230.	7.1	1
546	The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial. <i>European Journal of Heart Failure</i> , 2019, 21, 334-336.	7.1	1
547	Heart failure prevention with sodiumâ€‘glucose cotransporter 2 inhibitors. <i>Journal of Diabetes</i> , 2019, 11, 601-604.	1.8	1
548	Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter?. <i>Current Heart Failure Reports</i> , 2019, 16, 12-20.	3.3	1
549	Commentary: Failure predicting failure: The right ventricle after left ventricular assist device implantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1861-1862.	0.8	1
550	Disparities in Discharge Disposition After Hospitalizations for Decompensated Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 95-97.	0.8	1
551	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529.	3.9	1
552	FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	1
553	Hostile Work Environment. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2410-2412.	2.8	1
554	Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. <i>Circulation: Heart Failure</i> , 2021, 14, e008147.	3.9	1
555	Target trial emulations: bridging the gap between clinical trial and realâ€‘world data. <i>European Journal of Heart Failure</i> , 2021, 23, 1708-1711.	7.1	1
556	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	1.6	1
557	Trends in prevalence of comorbidities in heart failure clinical trials. , 2020, 22, 1032.		1
558	Sodiumâ€‘Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. <i>Cardiac Failure Review</i> , 2019, 5, 169-172.	3.0	1

#	ARTICLE	IF	CITATIONS
559	Investigator-Reported Versus Adjudicated Clinical Events. Journal of the American College of Cardiology, 2021, 78, 1538-1540.	2.8	1
560	Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). Romanian Journal of Laboratory Medicine, 2018, 26, 271-281.	0.2	1
561	Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. European Journal of Heart Failure, 2022, 24, 678-680.	7.1	1
562	Assessing health status after discharge for decompensated heart failure: a <scp>patientâ€centred</scp> priority. European Journal of Heart Failure, 2022, 24, 1030-1032.	7.1	1
563	Response to Letter Regarding Article, â€œEffect of Short Call Admissions on Length of Stay and Quality of Care for Acute Decompensated Heart Failureâ€ Circulation, 2009, 119, .	1.6	0
564	The Hi-Tech Age of Heart Failure Management. Heart Failure Clinics, 2015, 11, xi-xii.	2.1	0
565	The Winning Team in Heart Failure: Dimensionality of Care Redesign. Heart Failure Clinics, 2015, 11, ix-x.	2.1	0
566	Biomarkers and Cancer Therapy-Related Cardiac Dysfunction. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
567	How to Best Identify Elderly Individuals Who May Develop Heart Failure. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
568	Dilemmas With Race and Heart Failure Treatment. Circulation: Heart Failure, 2016, 9, .	3.9	0
569	Left Ventricular Ejection Fraction in Patients With Acute Heart Failure: A Limited Tool?. Revista Espanola De Cardiología (English Ed), 2017, 70, 318-319.	0.6	0
570	Leadership in cardiology. European Heart Journal, 2017, 38, 2323-2323.	2.2	0
571	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. Expert Review of Cardiovascular Therapy, 2018, 16, 123-131.	1.5	0
572	Mihai Gheorghiade, MDâ€”Life and Concepts. American Journal of Therapeutics, 2018, 25, e453-e455.	0.9	0
573	With great power comes greatâ€ reliability. European Journal of Heart Failure, 2020, 22, 1708-1710.	7.1	0
574	Standardizing the standard: reporting health status in clinical trials. European Journal of Heart Failure, 2021, 23, 203-204.	7.1	0
575	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	0
576	Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials. European Journal of Heart Failure, 2021, 23, 590-592.	7.1	0

#	ARTICLE	IF	CITATIONS
577	Aetiology of heart failure is in the eye of the beholder: does it even matter?. European Journal of Heart Failure, 2021, 23, 614-616.	7.1	0
578	The Reply. American Journal of Medicine, 2021, 134, e357.	1.5	0
579	Sex Disparity Among Canadian Cardiologists in Academic Medicine: Differences in Scholarly Productivity and Academic Rank. Cureus, 2021, 13, e18687.	0.5	0
580	Abstract 11614: ASC Methylation and Outcomes in Heart Failure. Circulation, 2015, 132, .	1.6	0
581	Abstract 10902: Association Between Funding Sources and the Scope and Outcomes of Cardiovascular Clinical Trials: A Systematic Review. Circulation, 2015, 132, .	1.6	0
582	Abstract 14841: Definitions of Stage D Heart Failure and Survival: Comparing INTERMACS Profiles, ESC Criteria, and Physician Assessment. Circulation, 2015, 132, .	1.6	0
583	Abstract 252: Regional Variations in Access to Care Among U.S. Veterans With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, .	2.2	0
584	The inadequacy of cardiovascular safety reporting in breast cancer clinical trials.. Journal of Clinical Oncology, 2020, 38, e24100-e24100.	1.6	0
585	Annals for Hospitalists Inpatient Notes - Clinical Pearls“Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, HO2-HO3.	3.9	0
586	The Enabling Potential of Device Therapy for Heart Failure. Journal of Cardiac Failure, 2022, , .	1.7	0
587	Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game. European Journal of Heart Failure, 2022, 24, 885-886.	7.1	0
588	Abstract 19793: Relationship Between Self-care, Functional Health, and Health Resource Use in Adults With Congenital Heart Defects. Circulation, 2015, 132, .	1.6	0
589	Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial. Circulation, 2017, 136, .	1.6	0
590	Abstract 21161: Use of an Open Access Multi-Sponsor Data Sharing Platform in Cardiology. Circulation, 2017, 136, .	1.6	0